- Home
- MRVI vs SPXX Comparison
MRVI vs SPXX Comparison
Compare MRVI & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- SPXX
- Stock Information
- Founded
- MRVI 2014
- SPXX 2004
- Country
- MRVI United States
- SPXX United States
- Employees
- MRVI N/A
- SPXX N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- SPXX Trusts Except Educational Religious and Charitable
- Sector
- MRVI Health Care
- SPXX Finance
- Exchange
- MRVI Nasdaq
- SPXX Nasdaq
- Market Cap
- MRVI 376.2M
- SPXX 322.7M
- IPO Year
- MRVI 2020
- SPXX N/A
- Fundamental
- Price
- MRVI $2.81
- SPXX $17.97
- Analyst Decision
- MRVI Hold
- SPXX
- Analyst Count
- MRVI 9
- SPXX 0
- Target Price
- MRVI $5.25
- SPXX N/A
- AVG Volume (30 Days)
- MRVI 940.3K
- SPXX 51.3K
- Earning Date
- MRVI 11-06-2025
- SPXX 01-01-0001
- Dividend Yield
- MRVI N/A
- SPXX 7.55%
- EPS Growth
- MRVI N/A
- SPXX N/A
- EPS
- MRVI N/A
- SPXX N/A
- Revenue
- MRVI $219,830,000.00
- SPXX N/A
- Revenue This Year
- MRVI N/A
- SPXX N/A
- Revenue Next Year
- MRVI $7.23
- SPXX N/A
- P/E Ratio
- MRVI N/A
- SPXX N/A
- Revenue Growth
- MRVI N/A
- SPXX N/A
- 52 Week Low
- MRVI $1.67
- SPXX $13.57
- 52 Week High
- MRVI $9.50
- SPXX $16.05
- Technical
- Relative Strength Index (RSI)
- MRVI 60.20
- SPXX 43.91
- Support Level
- MRVI $2.61
- SPXX $18.01
- Resistance Level
- MRVI $2.80
- SPXX $18.40
- Average True Range (ATR)
- MRVI 0.16
- SPXX 0.15
- MACD
- MRVI 0.04
- SPXX -0.02
- Stochastic Oscillator
- MRVI 76.09
- SPXX 13.73
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.